Patents Assigned to Pandion Therapeutics, Inc.
  • TARGETED IMMUNOTOLERANCE
    Publication number: 20210277085
    Abstract: Methods and compounds for conferring site-specific or local immune privilege.
    Type: Application
    Filed: November 20, 2018
    Publication date: September 9, 2021
    Applicant: Pandion Therapeutics, Inc.
    Inventors: Nathan HIGGINSON-SCOTT, Joanne L. VINEY, Jyothsna VISWESWARAIAH, Erik Robert SAMPSON, Kevin Lewis OTIPOBY
  • Targeted immunotolerance
    Patent number: 10676516
    Abstract: Methods and compounds for conferring site-specific or local immune privilege.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: June 9, 2020
    Assignee: PANDION THERAPEUTICS, INC.
    Inventors: Joanne L. Viney, Nathan Higginson-Scott
  • IL-2 muteins
    Patent number: 10174091
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 8, 2019
    Assignee: Pandion Therapeutics, Inc.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • IL-2 muteins
    Patent number: 10174092
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 8, 2019
    Assignee: Pandion Therapeutics, Inc.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby